Comparison of Software for Bayesian Network Meta-Analysis: A Case Study of Binomial Outcomes in Ulcerative Colitis

Author(s)

Ainsworth C1, Youn JH2, Petersohn S2, Gittfried A2, Jevdjevic M3, Piena M4
1OPEN Health Evidence & Access, Manchester, UK, 2OPEN Health Evidence & Access, Rotterdam, Netherlands, 3OPEN Health Evidence & Access, Rotterdam, GE, Netherlands, 4OPEN Health Evidence & Access, Rotterdam, ZH, Netherlands

Presentation Documents

OBJECTIVES: Numerous software are available for performing Bayesian network meta-analysis (NMA), however WinBUGS remains the preferred option, with code provided in the National Institute of Health and Care Excellence Technical Support Document widely adopted. Alternative software may offer varying performance, running time and user experience. This case study compares results using different software to perform NMAs of binomial outcomes assessing the relative effects of treatments for patients with ulcerative colitis.

METHODS: Previously published NMAs conducted using OpenBUGS were replicated using the R packages R2WinBUGS and multinma to run WinBUGS and Stan, respectively, and their results were compared. Analyses were stratified by prior exposure to anti-tumour necrosis factor (anti-TNF) therapy and, data allowing, comprised the following outcomes at induction and maintenance: response, remission, mucosal healing, and discontinuations due to adverse events. Results from 13 NMAs were compared in terms of point estimates (odds ratios [ORs]), credible intervals (CrI), treatment rankings, and subsequent conclusions, as well as considering user experience.

RESULTS: Outputs were similar across software for all NMAs. For example, mean ORs for infliximab versus adalimumab were consistent across the different software in the fixed-effect (FE) NMA of response in anti-TNF naïve patients at induction: 2.19 [95% CrI: 1.35-3.55] using OpenBUGS vs. 2.51 [1.52-3.95] using WinBUGS vs. 2.44 [1.51-3.93] using Stan. Further, conclusions aligned across software, with no changes to treatment rankings. All networks were too small to give reliable estimates for random-effects models using OpenBUGS and WinBUGS, but comparable results to FE analyses were observed using Stan (2.43 [1.34-4.38]). Finally, Stan required less running time and was less computationally demanding.

CONCLUSIONS: Comparing software resulted in consistent outcomes and interpretations. While these results may not be generalizable to all network shapes and sizes, this study demonstrates that Stan provides a valid alternative and may be advantageous both in terms of performance and user experience.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

MSR130

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Comparative Effectiveness or Efficacy, Meta-Analysis & Indirect Comparisons

Disease

STA: Biologics & Biosimilars

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×